Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway
- PMID: 24651605
- PMCID: PMC4243708
- DOI: 10.1038/gim.2014.22
Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway
Erratum in
- Genet Med. 2014 Jul;16(7):568. Chen, Rui [added]
Abstract
Purpose: The endoplasmic reticulum-associated degradation pathway is responsible for the translocation of misfolded proteins across the endoplasmic reticulum membrane into the cytosol for subsequent degradation by the proteasome. To define the phenotype associated with a novel inherited disorder of cytosolic endoplasmic reticulum-associated degradation pathway dysfunction, we studied a series of eight patients with deficiency of N-glycanase 1.
Methods: Whole-genome, whole-exome, or standard Sanger sequencing techniques were employed. Retrospective chart reviews were performed in order to obtain clinical data.
Results: All patients had global developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), elevated liver transaminases (6/7), microcephaly (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), and seizures (4/8). The nonsense mutation c.1201A>T (p.R401X) was the most common deleterious allele.
Conclusion: NGLY1 deficiency is a novel autosomal recessive disorder of the endoplasmic reticulum-associated degradation pathway associated with neurological dysfunction, abnormal tear production, and liver disease. The majority of patients detected to date carry a specific nonsense mutation that appears to be associated with severe disease. The phenotypic spectrum is likely to enlarge as cases with a broader range of mutations are detected.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Comment in
-
The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated.Genet Med. 2014 Oct;16(10):736-7. doi: 10.1038/gim.2014.23. Epub 2014 Mar 20. Genet Med. 2014. PMID: 24651604 No abstract available.
References
-
- Takahashi N. Demonstration of a new amidase acting on glycopeptides. Biochem Biophys Res Commun. 1977;76:1194–1201. - PubMed
-
- Plummer TH, Jr, Elder JH, Alexander S, Phelan AW, Tarentino AL. Demonstration of peptide:N-glycosidase F activity in endo-beta-N-acetylglucosaminidase F preparations. J Biol Chem. 1984;259:10700–10704. - PubMed
-
- Xin F, Wang S, Song L, Liang Q, Qi Q. Molecular identification and characterization of peptide: N-glycanase from Schizosaccharomyces pombe. Biochem Biophys Res Commun. 2008;368:907–912. - PubMed
-
- Masahara-Negishi Y, Hosomi A, Della Mea M, Serafini-Fracassini D, Suzuki T. A plant peptide: N-glycanase orthologue facilitates glycoprotein ER-associated degradation in yeast. Biochim Biophys Acta. 2012;1820:1457–1462. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials